BUZZ-Vanda rises as nausea drug shows promise for GLP-1 side effects** Shares of drugmaker Vanda Pharmaceuticals VNDA.O rise 7% to $4.71 premarket
** Co says its experimental drug tradipitant significantly reduces nausea and vomiting in people taking the popular weight-loss drug Wegovy, according to results from a new clinical trial
** Study met main goal, 29.3% on tradipitant vomited vs 58.6% on placebo; also reduced severe nausea - VNDA
** Co says late-stage trial planned for 2026
** GLP-1 market exceeds $50 bln globally; tradipitant could boost adherence - VNDA
** Up to last close, stock down ~8% YTD
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.